GlassScriptPhysician profile
David S Rabin
NPI 1861654840
$7,788.38
in general payments reported to CMS, 2019-2025
28 companies · $1,845 in 2025
The $1,845 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $408 · 2020: $346 · 2021: $1,016 · 2022: $1,001 · 2023: $1,251 · 2024: $1,922 · 2025: $1,845.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,982 · Education: $34.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,982.44 |
| Education | $34.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,884.79 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,330.16 | 2020-2025 | Xifaxan, Plenvu, Trulance |
| Janssen Biotech, INC. | $610.29 | 2019-2025 | Tremfya, Stelara |
| Gilead Sciences, INC. | $591.01 | 2019-2024 | Epclusa |
| Merck Sharp & Dohme LLC | $338.58 | 2019-2024 | Dificid |
| Lilly USA, LLC | $329.43 | 2024-2025 | Omvoh |
| Takeda Pharmaceuticals U.S.A., INC. | $289.30 | 2019-2025 | Entyvio |
| Genzyme Corporation | $272.89 | 2023-2025 | |
| Ironwood Pharmaceuticals, INC | $188.93 | 2021-2025 | Linzess |
| Regeneron Healthcare Solutions, INC. | $188.66 | 2023-2025 | Dupixent |
| Qol Medical, LLC | $169.72 | 2023-2024 | Sucraid, Sucraid |
| Pfizer INC. | $165.21 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $151.28 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $144.26 | 2023-2025 | Ibsrela |
| Celltrion USA INC. | $143.88 | 2024-2025 | Vegzelma, Zymfentra |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $126.83 | 2024-2025 | Rezdiffra, Resmetirom |
| Braintree Laboratories, INC. | $125.74 | 2019-2021 | |
| Celgene Corporation | $114.78 | 2022-2024 | Zeposia |
| Organon LLC | $93.03 | 2023-2025 | Hadlima, Renflexis |
| Nestle Healthcare Nutrition INC. | $87.63 | 2021-2023 | |
| Redhill Biopharma INC. | $85.17 | 2020-2023 | Talicia, Aemcolo, Movantik |
| Intercept Pharmaceuticals, INC. | $80.63 | 2019-2024 | |
| Boston Scientific Corporation | $73.44 | 2021-2024 | Varithena Administration Pack |
| Medtronic, INC. | $54.48 | 2023-2024 | Interstim, Signia |
| Ipsen Biopharmaceuticals, INC | $50.51 | 2024-2025 | Iqirvo |
| Aimmune Therapeutics, INC. | $42.08 | 2025 | Zenpep |
| Daiichi Sankyo INC. | $36.78 | 2025 | Injectafer |
| Exact Sciences Corporation | $18.89 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Rabin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.